Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00795327
Recruitment Status : Completed
First Posted : November 21, 2008
Last Update Posted : November 20, 2019
Information provided by (Responsible Party):
Bausch Health Americas, Inc.

Brief Summary:


Evaluate the degree of correction attainable with Poly-L-Lactic Acid(Sculptra) for the correction of hill and valley acne scarring


Document types and incidence of device adverse events with Poly-L-Lactic Acid(Sculptra) therapy.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Device: Sculptra (Poly-L-Lactic Acid Dermal Implant) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Canadian Study of the Use of Injectable Poly-L-Lactic Acid Dermal Implant for the Treatment of Hill and Valley Acne Scarring
Study Start Date : October 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Scars

Arm Intervention/treatment
Experimental: 1
single arm study
Device: Sculptra (Poly-L-Lactic Acid Dermal Implant)
Drug Device study

Primary Outcome Measures :
  1. Physician Scar Improvement Scale (PSIS) [ Time Frame: At each visit ]
  2. Self-Assessed Scar Improvement Scale (SASIS). [ Time Frame: At each visit ]

Secondary Outcome Measures :
  1. Degree of subject satisfaction with treatment [ Time Frame: At each Visit ]
  2. Adverse events [ Time Frame: At each visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatient seeking therapy for correction of hill and valley acne scarring.
  • Ability and willingness to understand and comply with requirements of the trial

Exclusion Criteria:

  • The subject has active acne or chronic skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster
  • History of presence of keloid formation or hypertrophic scars
  • History of procedures that precipitate an active dermal inflammatory or hyperplastic response (i.e., epilation or radiofrequency laser and chemical peeling procedures) within one month of study entry
  • History of use of facial tissue augmenting therapy or aesthetic facial surgical therapy within six months prior to study entry
  • Concomitant anticoagulant therapy, antiplatelet therapy or has any bleeding disorders
  • History of unanticipated adverse reactions when treated with hyaluronic acid based products
  • Any condition which in the opinion of the investigator makes the patient unable to complete the study per protocol (e.g., patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments)
  • History of or current cancerous or pre-cancerous lesions in the area to be treated
  • Use of any investigational drugs or any other medical devices within 30 days of enrolment
  • Use of any prohibited medication within a proscribed time period before entry
  • Pregnancy
  • Recent use of Accutane (patient should not be on Accutane for the last 6 months)
  • History of allergic/anaphylactic reactions, including hypersensitivity to local anaesthetics (lidocaine)
  • Recent history of trauma in the face (less that 1 year)
  • Previous of Dermalive or Dermadeep

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00795327

Layout table for location information
Sanofi-Aventis Administrative Office
Laval, Canada
Sponsors and Collaborators
Bausch Health Americas, Inc.
Layout table for investigator information
Study Chair: Mary Tzortzis Sanofi-Aventis Canada Inc.

Layout table for additonal information
Responsible Party: Bausch Health Americas, Inc. Identifier: NCT00795327    
Other Study ID Numbers: POLYL_L_02508
First Posted: November 21, 2008    Key Record Dates
Last Update Posted: November 20, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases